VivoSim Labs VIVS
NASDAQ VIVS
$0.29 +0.01 (+3.86%)
As of: Aug 21, 2026 · 3:59 PM EDT

VivoSim Labs (VIVS) Short term Debt (2024)

VivoSim Labs (VIVS) posted quarterly Short term Debt of $353000.0 for Q4 2024.

VivoSim Labs (VIVS) Short term Debt (2024) Analysis & Trends

VivoSim Labs' Short term Debt history runs 1 years deep, the most recent figure standing at $353000.0 for Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 VivoSim Labs 1.49 Mn 1.49 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2024 353,000.00